Limits...
ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques.

Lemperle G, Knapp TR, Sadick NS, Lemperle SM - Aesthetic Plast Surg (2009)

Bottom Line: No serious side effects have been reported to date according to the FDA's MAUDE reporting database.The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction.This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

View Article: PubMed Central - PubMed

Affiliation: Division of Plastic Surgery, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103, USA. glemperle@aol.com

ABSTRACT
After more than 25 years of research and development, in October 2006 ArteFill became the first and only permanent injectable wrinkle filler to receive FDA approval. ArteFill is a third-generation polymeric microsphere-based filler, following its predecessor Artecoll, which was marketed outside the United States between 1994 and 2006. ArteFill is approved for the correction of nasolabial folds and has been used in over 15,000 patients since its U.S. market introduction in February 2007. No serious side effects have been reported to date according to the FDA's MAUDE reporting database. ArteFill consists of polymethylmethacrylate (PMMA) microspheres (20% by volume), 30-50 microm in diameter, suspended in 3.5% bovine collagen solution (80% by volume) and 0.3% lidocaine. The collagen carrier is absorbed within 1 month after injection and completely replaced by the patient's own connective tissue within 3 months. Each cc of ArteFill contains approximately six million microspheres and histological studies have shown that long-term wrinkle correction consists of 80% of the patient's own connective tissue and 20% microspheres. The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction. This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

Show MeSH

Related in: MedlinePlus

The “tunneling technique”: Note the relationship of dermal thickness in a wrinkle and the diameter of a 26G needle—both are around 0.4 mm. The ArteFill strand is delivered while withdrawing the needle ([3] with permission from Elsevier)
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2872009&req=5

Fig9: The “tunneling technique”: Note the relationship of dermal thickness in a wrinkle and the diameter of a 26G needle—both are around 0.4 mm. The ArteFill strand is delivered while withdrawing the needle ([3] with permission from Elsevier)

Mentions: Locating the correct plane for the injection of ArteFill permanent filler is of utmost importance. The thickness of the facial dermis varies between 0.4 mm in lids and 1.2 mm in the forehead and cheeks (Fig. 8). In a deep crease the thickness of the dermis may be reduced to only one-third of its normal thickness [3]. The outer diameter of a 26G needle is 0.45 mm and can be used as a depth gauge to estimate the thickness of the dermis. The facial dermis is only about twice as thick as a 26G needle (Fig. 9).Fig. 8


ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques.

Lemperle G, Knapp TR, Sadick NS, Lemperle SM - Aesthetic Plast Surg (2009)

The “tunneling technique”: Note the relationship of dermal thickness in a wrinkle and the diameter of a 26G needle—both are around 0.4 mm. The ArteFill strand is delivered while withdrawing the needle ([3] with permission from Elsevier)
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2872009&req=5

Fig9: The “tunneling technique”: Note the relationship of dermal thickness in a wrinkle and the diameter of a 26G needle—both are around 0.4 mm. The ArteFill strand is delivered while withdrawing the needle ([3] with permission from Elsevier)
Mentions: Locating the correct plane for the injection of ArteFill permanent filler is of utmost importance. The thickness of the facial dermis varies between 0.4 mm in lids and 1.2 mm in the forehead and cheeks (Fig. 8). In a deep crease the thickness of the dermis may be reduced to only one-third of its normal thickness [3]. The outer diameter of a 26G needle is 0.45 mm and can be used as a depth gauge to estimate the thickness of the dermis. The facial dermis is only about twice as thick as a 26G needle (Fig. 9).Fig. 8

Bottom Line: No serious side effects have been reported to date according to the FDA's MAUDE reporting database.The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction.This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

View Article: PubMed Central - PubMed

Affiliation: Division of Plastic Surgery, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103, USA. glemperle@aol.com

ABSTRACT
After more than 25 years of research and development, in October 2006 ArteFill became the first and only permanent injectable wrinkle filler to receive FDA approval. ArteFill is a third-generation polymeric microsphere-based filler, following its predecessor Artecoll, which was marketed outside the United States between 1994 and 2006. ArteFill is approved for the correction of nasolabial folds and has been used in over 15,000 patients since its U.S. market introduction in February 2007. No serious side effects have been reported to date according to the FDA's MAUDE reporting database. ArteFill consists of polymethylmethacrylate (PMMA) microspheres (20% by volume), 30-50 microm in diameter, suspended in 3.5% bovine collagen solution (80% by volume) and 0.3% lidocaine. The collagen carrier is absorbed within 1 month after injection and completely replaced by the patient's own connective tissue within 3 months. Each cc of ArteFill contains approximately six million microspheres and histological studies have shown that long-term wrinkle correction consists of 80% of the patient's own connective tissue and 20% microspheres. The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction. This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

Show MeSH
Related in: MedlinePlus